AnaCardio Raises €62.5M Series B to Advance Oral Heart Failure Therapy AC01

AnaCardio Secures €62.5 Million in Series B Funding

AnaCardio, a privately held clinical-stage Swedish biopharmaceutical company, has raised €62.5 million in Series B funding. The round was completed on September 29, 2026. No lead investor or additional participants were disclosed.

What AnaCardio Does

AnaCardio is developing first-in-class oral contractile agents for heart failure. The company was founded on research from Karolinska Institutet and is headquartered in Solna, Stockholm.

Its lead candidate, AC01, is an oral ghrelin receptor agonist that was in-licensed from Helsinn. In the Phase 1b/2a GOAL-HF1 study in patients with heart failure with reduced ejection fraction (HFrEF), AC01 showed a favorable safety profile and sustained improvements in cardiac function. The results were published in The Lancet.

Use of Funds

According to the company, AnaCardio is now preparing AC01 for registrational development. The Series B proceeds will support this next stage of clinical advancement.

Deal Details

• Company: AnaCardio
• Round: Series B
• Amount: €62.5 million
• Date: September 29, 2026
• Lead Investor: Not disclosed
• Other Investors: Not disclosed
• Stage: Clinical-stage biopharmaceutical
• Location: Solna, Stockholm, Sweden

Why It Matters

Heart failure remains a significant area of unmet medical need, and oral contractile agents could offer a differentiated approach if successfully developed. AnaCardio's progression toward registrational development marks a key milestone for the company and its lead asset, AC01.

For investors and acquirers tracking late-stage cardiovascular assets, AnaCardio's Series B signals continued confidence in its clinical strategy and the potential of oral ghrelin receptor agonism in HFrEF.